

Drug Discovery and Development



Quantitation of Insulin Glargine in Human Plasma with a Combination of Immunocapture-Based Target Enrichment and Trap-and-Elute Microflow LC-MS/MS

Using the SCIEX Biologics Bioanalysis (BioBA) assay and M3 MicroLC system to improve detection limits

Remco van Soest and Yihan Li SCIEX, Redwood City, CA, USA

Overview

Insulin glargine, a recombinant protein, is a long-acting insulin analogue given daily to diabetes patients to help control blood sugar level. Marketed as Lantus, insulin glargine has been one of the best-selling pharmaceutical products for the past five years. As such, there is tremendous interest within the clinical research community in analyzing and studying insulin glargine in biological samples.

Who Should Read This: Senior Scientists, Lab Directors

Focus: Quantitation of insulin glargine through a combination of immunocapture-based target enrichment and trap-and-elute microflow I C-MS/MS.

Goal: Determine how much sensitivity can be gained by using trap-and-elute microflow liquid chromatography instead of traditional liquid chromatography in a method that combines immunocapture-based target enrichment with LC-MS/MS for quantitation of insulin glargine.

Problem: Traditional methods of quantifying insulin glargine, ELISA and LC-MS/MS, have significant drawbacks. ELISA provides poor specificity and cannot distinguish insulin glargine from other insulin analogs. Traditional LC-MS/MS provides specificity, but because of ion suppression and interference from the sample matrix can lack the sensitivity requiredfor contemporary clinical research.

Key Challenges:

- ELISA and LC-MS/MS, the traditional methods of quantifying insulin glargine, have significant drawbacks
- ELISA suffers from poor specificity; anti-insulin antibodies cannot distinguish insulin glargine from other insulin analogs
- Traditional LC at mL/min flow rates combined with MS/MS sometimes fails to provide the sensitivity needed when sample quantities are limited
- Insulin and insulin analogs are known to show significant carryover in HPLC due to non-specific binding to the stationary phase and this carryover negatively affects quantitative accuracy and method robustness

Key Features:

- · Enrichment through immunocapture-based target enrichment
- · High specificity from the use of unique MS/MS transitions
- 5x better sensitivity than traditional LC-MS/MS
- Increased robustness using trap-and-elute workflow

Experimental Design

Sample Preparation: Samples were prepared by spiking insulin glargine (Myoderm) and bovine insulin (internal standard, Sigma-Aldrich) into human plasma-K2 EDTA (BioreclamationIVT).

Streptavidin-coated magnetic beads were from SCIEX (BioBA High Capacity Enrichment Sample Preparation Kit, P/N 5041071). The antibody for immunocapture was biotinylated antiinsulin and proinsulin mouse monoclonal (P/N ab20756, Abcam). A 250 μL plasma sample was processed, resulting in 115 μL of enriched insulin glargine for injection into the LC-MS/MS system. See Reference 1 for details on the sample preparation method. Because leftover traces of the phosphate buffer solution can cause tailing of the insulin glargine peak, the washing buffer was replaced with 10 mM ammonium bicarbonate for the last wash step after immunocapture.






Figure 1. Immunocapture-Based Sample Preparation Workflow.



Figure 2. M3 MicroLC-TE System. The system includes two microflow LC gradient pumps and an integrated autosampler with a 6 plate capacity.

HPLC: For the traditional flow rate (mL/min) experiments, a SCIEX ExionLC[™] AD HPLC system was used with the following column and conditions:

| Injection Volume | 30 µL | | | | |
|--------------------|--|--|--|--|--|
| Autosampler Wash | 20/20/60 methanol/acetonitrile/isopropyl alcohol | | | | |
| Mobile Phase A | Water with 0.1% formic acid | | | | |
| Mobile Phase B | Acetonitrile with 0.1% formic acid | | | | |
| Gradient | 10-50% B over 5 min with a 4 min wash at 60% B | | | | |
| Flow Rate | 500 μL/min | | | | |
| Column | 100 x 2.1 mm Kinetex C18 2.6 μm 100 Å (Phenomenex) | | | | |
| Column Temperature | 40° C | | | | |

For microflow experiments, a SCIEX M3 MicroLC-TE system was used in trap-and-elute mode. The following columns and conditions were used:

| Injection Volume | 30 μL | | | |
|----------------------|--|--|--|--|
| Autosampler Wash | Wash 1: 66.5/30/3.5 acetonitrile/water/acetic acid Wash 2: water with 0.1% formic acid | | | |
| Loading Solvent A | Water with 0.1% formic acid | | | |
| Loading Solvent B | Acetonitrile with 0.25% trifluoroacetic acid | | | |
| Trap Loading/Washing | Loading for 2 min at 50 µL/min with 0% B, washing for 10 min at 70 µL/min with 60% B | | | |
| Trap Column | 10 x 0.5 mm 5 μm 120 Å ChromXP™ C18 CL column (SCIEX) | | | |
| Mobile Phase A | Water with 0.1% formic acid | | | |
| Mobile Phase B | Acetonitrile with 0.1% formic acid | | | |
| Gradient | 10–50% B over 5 min with a 7 min wash at 60% B | | | |
| Flow Rate | 10 μL/min | | | |
| Column | MonoCap Fast-Flow 100 x 0.2 mm (P/N 5020-10124, GL Sciences) | | | |
| Column Temperature | 40° C | | | |






Figure 3. Valve Positions for the Trap-and-Elute Microflow LC Method. In the configuration on the left, sample is loaded onto the trap column at a high flow. Once sample loading and washing any non-retained matrix components to waste are completed, the auxiliary valve switches to Inject, and the LC-MS/MS analysis starts (configuration on the right). The trap-and-elute workflow provides faster loading of samples and removal of matrix components, thereby improving throughput and robustness.

Mass Spectrometry: A SCIEX QTRAP® 6500+ LC-MS/MS system with IonDrive™ was used in multiple-reaction monitoring (MRM) mode. For quantitation the transition *m*/*z* 867.0→984.0 was used, while two additional transitions (*m*/*z* 867.0→992.4 and *m*/*z* 1011.4→1179.5) of insulin glargine where monitored for confirmation. The *m*/*z* 956.6→1115.2 transition was used for the bovine insulin internal standard. For the microflow LC experiments, the standard electrode was replaced with a 25 μm ID electrode (SCIEX). Source conditions for both traditional LC and microflow LC are listed in Table 1. See Reference 1 for other MS parameters. SCIEX MultiQuant software version 3.0.2 was used for integration and data analysis. A 1 point Gaussian smoothing was applied, and a linear regression with weighting 1/*x*² was used for all calibration curves.

| | Traditional LC | Microflow LC | | |
|------------------|----------------|--------------|--|--|
| Electrode ID | 100 μm | 25 μm | | |
| Curtain Gas | 20 | 20 | | |
| IonSpray Voltage | 5500 | 5000 | | |
| Temperature (°C) | 600 250 | | | |
| Ion Source Gas 1 | 50 | 20 | | |
| Ion Source Gas 2 | 65 | 20 | | |

Table 1. Source Parameters.

Sensitivity Improvement

Microflow LC, using 0.3 mm ID columns at flow rates of 5–20 μ L/min flow rates, can improve LC-MS sensitivity by a factor of up to 10 compared to traditional 2.1–3 mm ID columns at flow rates of 0.5–1 mL/min.² For insulin glargine, signal-to-noise was improved by a factor of approximately 3.5 times when using microflow LC (Figure 4). Calibration curves from 10 pg/mL to 10,000 pg/mL were acquired using both the traditional LC and trap-and-elute microflow LC methods. Each sample was injected in triplicate. Accuracy and precision using both traditional LC and microflow LC are summarized in Table 2.

LLOQ at traditional flow rates was 50 pg/mL, which was the same quantitation limit reported previously.^{1,3} LLOQ using the microflow LC workflow was 10 pg/mL (Figure 5), which is an improvement of 5x. This is considerably lower than the required detection limit of 70 pg/mL for clinical use.⁴






Figure 4. Sensitivity Comparison. Microflow LC-MS/MS analysis of insulin glargine in a plasma sample spiked at the 100 pg/mL level improved signal-to-noise by a factor of approximately 3.5 times compared to LC-MS/MS at traditional flow rates.

| Actual Concentration (pg/mL) | Traditional LC-MS/MS | | | Microflow LC-MS/MS | | |
|------------------------------|--|--------------|--------|--|--------------|--------|
| | Mean Calculated Concentration (pg/mL) | Accuracy (%) | CV (%) | Mean Calculated Concentration (pg/mL) | Accuracy (%) | CV (%) |
| 10 | N/A | N/A | N/A | 10.2 | 102 | 10 |
| 25 | N/A | N/A | N/A | 23.0 | 92 | 14 |
| 50 | 49.2 | 98 | 13 | 50.9 | 102 | 3.4 |
| 100 | 95.7 | 96 | 9.6 | 104 | 104 | 5.8 |
| 500 | 482 | 96 | 1.4 | 486 | 97 | 10 |
| 1,000 | 990 | 99 | 0.61 | 1,056 | 106 | 3.4 |
| 5,000 | 5,276 | 105 | 1.3 | 4,888 | 98 | 1.3 |
| 10,000 | 10,300 | 103 | 1.3 | 9,922 | 99 | 0.50 |

Table 2. Standard Curve Data for the Traditional and Microflow LC-MS/MS Methods




Figure 5. Extracted Ion Chromatograms for a Blank and Sample. At the 10 pg/mL LLOQ, the signal-to-noise ratio was approximately 10.






Figure 6. Calibration Curve for the Quantitation of Insulin Glargine using Microflow LC-MS/MS.

Carryover

Insulin and insulin analogs are known to show significant carryover in HPLC due to non-specific binding to the stationary phase. Carryover in the microflow LC method was reduced by using a silica-based monolithic column and by washing the trap off line from the analytical column for 10 minutes. Carryover was reduced to below the noise level within the calibration curve range measured (Figure 7).




Figure 7. Carryover After Injecting the Extract of a Sample Spiked at the 10,000 pg/mL Level. Carryover based on peak intensity was less than 0.01%, and low enough to declare 10,000 pg/mL as the ULOQ.



Conclusion

The trap-and-elute microflow LC-MS/MS method, in combination with an immunocapture-based target enrichment workflow, achieved a LLOQ of 10 pg/mL insulin glargine in human plasma. This was 5x better than data generated by LC-MS/MS at traditional mL/min flow rates. By using a monolithic column and washing the trap column extensively off line from the analytical column, carryover of <0.01% was achieved, allowing quantitation up to 10,000 pg/mL. The trap-and-elute technique provided fast loading of large volume samples, while protecting the analytical column and mass spectrometer from contaminants, resulting in a more robust method.

References

- SCIEX vMethod™ Application for Pharma and BioPharma Markets, Combined Immunoaffinity-LC-MS/MS Method for Quantifying Insulin Glargine in Human Plasma
- Covey T.R., Schneider B.B., Kovarik, Corr, Javahari et al.; The Central Analytical Figures of Merit of ESI, MALDI, and APCI.; Cole RB, ed. *Electrospray and MALDI mass* spectrometry. 2010, Chapter 13. Hoboken: John Wiley & Sons, Inc.
- Fast, sensitive, robust Immunocapture/SPE-LC-MS/MS workflow for quantitation of insulin Analogues in human plasma, Poster presented at ASMS 2015
- 4. Insulin Assay Standardization, *Diabetes Care*, Volume 33, Number 1, January 2010

Who is SCIEX? SCIEX company's global leadership and worldclass service and support in the capillary electrophoresis and liquid chromatography-mass spectrometry industry have made it a trusted partner to thousands of the scientists and lab analysts worldwide who are focused on basic research, drug discovery and development, food and environmental testing, forensics and clinical research.

Contact Us: sciex.com/contact-us

For Research Use Only. Not for use in diagnostic procedures.

© 2016 AB SCIEX. SCIEX is part of AB SCIEX. The trademarks mentioned herein are the property of AB Sciex Pte. Ltd. or their respective owners. AB SCIEXTM is being used under license. Mention of trade names or commercial products in this publication is solely for the purpose of providing specific information and does not imply recommendation or endorsement by the USDA.

Publication number: RUO-MKT-02-5037-A

